Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| Allogene Therapeutics, Inc.ALLO · Entity 5243 | General Counsel | March 14, 2023 | March 16, 2023 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
Allogene Therapeutics, Inc.
Report date March 14, 2023 · Filed March 16, 2023
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 556,049 |
Reported balance
After 2023-03-14 transaction · row 1
Account or security details depend on footnotes; rows are not merged.
1 source rowRow 1 · 2023-03-14 · Tax withholding · Disposed 23,628 · Balance 556,049 F1: Represents the number of shares sold by the reporting person to cover tax withholding obligations in connection with the vesting of restricted stock units. This sale is mandated by the Issuer's election under its equity incentive plan to require the satisfaction of tax withholding obligations to be funded by a "sell to cover" transaction and does not represent a discretionary trade by the reporting person. F2: Includes 2,000 shares of the Issuer's common stock acquired by the reporting person on March 15, 2023 pursuant to an employee stock purchase program. |
Filing footnotes · ownership attribution and instrument terms
F1: Represents the number of shares sold by the reporting person to cover tax withholding obligations in connection with the vesting of restricted stock units. This sale is mandated by the Issuer's election under its equity incentive plan to require the satisfaction of tax withholding obligations to be funded by a "sell to cover" transaction and does not represent a discretionary trade by the reporting person.
F2: Includes 2,000 shares of the Issuer's common stock acquired by the reporting person on March 15, 2023 pursuant to an employee stock purchase program.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| March 14, 2023 Filed Mar 16, 2023 16:46 UTC | Allogene Therapeutics, Inc. ALLO · Entity 5243 | Tax withholdingCommon Stock | 23,628 | $5.67 | $133,970.76 |
DisclosureSEC source: 0001593968-23-000491 · primary_01.xml · nonDerivative · entry 1 Bhavnagri Veer · CIK 0001808980 · General Counsel 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 556,049 F1 · shares: Represents the number of shares sold by the reporting person to cover tax withholding obligations in connection with the vesting of restricted stock units. This sale is mandated by the Issuer's election under its equity incentive plan to require the satisfaction of tax withholding obligations to be funded by a "sell to cover" transaction and does not represent a discretionary trade by the reporting person. F2 · balance_after: Includes 2,000 shares of the Issuer's common stock acquired by the reporting person on March 15, 2023 pursuant to an employee stock purchase program. Read SEC document |
| February 13, 2023 Filed Feb 14, 2023 17:10 UTC | Allogene Therapeutics, Inc. ALLO · Entity 5243 | SaleCommon Stock | 3,000 | $6.85 | $20,550.00 |
DisclosureSEC source: 0001593968-23-000317 · primary_01.xml · nonDerivative · entry 1 Bhavnagri Veer · CIK 0001808980 · General Counsel 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 577,677 F1 · acquired: 1. The sale reported in this Form 4 was effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person in May 2022. Read SEC document |
| January 17, 2023 Filed Jan 18, 2023 18:10 UTC | Allogene Therapeutics, Inc. ALLO · Entity 5243 | SaleCommon Stock | 3,000 | $7.04 | $21,120.00 |
DisclosureSEC source: 0001593968-23-000168 · primary_01.xml · nonDerivative · entry 1 Bhavnagri Veer · CIK 0001808980 · General Counsel 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 580,677 F1 · shares: 1. The sale reported in this Form 4 was effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person in May 2022. Read SEC document |
| December 15, 2022 Filed Dec 19, 2022 16:29 UTC | Allogene Therapeutics, Inc. ALLO · Entity 5243 | SaleCommon Stock | 5,602 | $7.53 | $42,186.42 |
DisclosureSEC source: 0001593968-22-001742 · primary_01.xml · nonDerivative · entry 1 Bhavnagri Veer · CIK 0001808980 · General Counsel 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 583,677 F1 · shares: 1. The sale reported in this Form 4 was effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person in May 2022. F2 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $7.39 to $7.71, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth above. Read SEC document |
| March 23, 2022 Filed Mar 25, 2022 17:49 UTC | Allogene Therapeutics, Inc. ALLO · Entity 5243 | GrantStock Option (Right to Buy) · Derivative | 272,435 | $0.00 Strike: $9.69 | $0.00 |
DisclosureSEC source: 0001214659-22-004370 · marketforms-55857.xml · derivative · entry 2 Bhavnagri Veer · CIK 0001808980 · General Counsel 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 272,435 Underlying: Common Stock · 272,435 shares Expires 2032-03-23 F1 · derivative.exercise_date: 25% of the shares subject to the stock option shall vest on March 13, 2023, and the remaining shares shall vest in 36 equal monthly installments thereafter Read SEC document |
| March 23, 2022 Filed Mar 25, 2022 17:49 UTC | Allogene Therapeutics, Inc. ALLO · Entity 5243 | GrantCommon Stock | 175,438 | $0.00 | $0.00 |
DisclosureSEC source: 0001214659-22-004370 · marketforms-55857.xml · nonDerivative · entry 1 Bhavnagri Veer · CIK 0001808980 · General Counsel 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 589,279 Read SEC document |
| March 15, 2022 Filed Mar 17, 2022 17:59 UTC | Allogene Therapeutics, Inc. ALLO · Entity 5243 | SaleCommon Stock | 8,849 | $7.68 | $67,962.09 |
DisclosureSEC source: 0001214659-22-004086 · marketforms-55822.xml · nonDerivative · entry 1 Bhavnagri Veer · CIK 0001808980 · General Counsel 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 413,841 F1 · shares: Represents the number of shares sold by the reporting person to cover tax withholding obligations in connection with the vesting of restricted stock units. This sale is mandated by the Issuer's election under its equity incentive plan to require the satisfaction of tax withholding obligations to be funded by a "sell to cover" transaction and does not represent a discretionary trade by the reporting person. F2 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $7.64 to $7.72, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth above. F3 · balance_after: Includes 1021 shares of the Issuer's common stock acquired by the reporting person on March 15, 2022 pursuant to an employee stock purchase program. Read SEC document |
| September 15, 2021 Filed Sep 17, 2021 16:44 UTC | Allogene Therapeutics, Inc. ALLO · Entity 5243 | Exercise / conversionStock Option (Right to Buy) · Derivative | 5,000 | $0.00 Strike: $2.27 | $0.00 |
DisclosureSEC source: 0001214659-21-009625 · marketforms-53823.xml · derivative · entry 3 Bhavnagri Veer · CIK 0001808980 · General Counsel 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 112,300 Underlying: Common Stock · 5,000 shares Expires 2028-06-25 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F4 · derivative.exercise_date: 25% of the shares subject to the stock option vested on April 6, 2019, and the remaining shares vest in 36 equal monthly installments thereafter. Read SEC document |
| September 15, 2021 Filed Sep 17, 2021 16:44 UTC | Allogene Therapeutics, Inc. ALLO · Entity 5243 | SaleCommon Stock | 5,000 | $24.77 | $123,844.50 |
DisclosureSEC source: 0001214659-21-009625 · marketforms-53823.xml · nonDerivative · entry 2 Bhavnagri Veer · CIK 0001808980 · General Counsel 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 421,669 F2 · kind: The sale reported in this Form 4 was effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person in December 2020. F3 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $24.64 to $24.90, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth above. Read SEC document |
| September 15, 2021 Filed Sep 17, 2021 16:44 UTC | Allogene Therapeutics, Inc. ALLO · Entity 5243 | Exercise / conversionCommon Stock | 5,000 | $2.27 | $11,350.00 |
DisclosureSEC source: 0001214659-21-009625 · marketforms-53823.xml · nonDerivative · entry 1 Bhavnagri Veer · CIK 0001808980 · General Counsel 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 426,669 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · balance_after: Includes 316 shares of the Issuer's common stock acquired by the reporting person on September 15, 2021 pursuant to an employee stock purchase program. Read SEC document |
| August 16, 2021 Filed Aug 17, 2021 16:05 UTC | Allogene Therapeutics, Inc. ALLO · Entity 5243 | Exercise / conversionStock Option (Right to Buy) · Derivative | 5,000 | $0.00 Strike: $2.27 | $0.00 |
DisclosureSEC source: 0001214659-21-008761 · marketforms-53604.xml · derivative · entry 3 Bhavnagri Veer · CIK 0001808980 · General Counsel 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 117,300 Underlying: Common Stock · 5,000 shares Expires 2028-06-25 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F3 · derivative.exercise_date: 25% of the shares subject to the stock option vested on April 6, 2019, and the remaining shares vest in 36 equal monthly installments thereafter. Read SEC document |
| August 16, 2021 Filed Aug 17, 2021 16:05 UTC | Allogene Therapeutics, Inc. ALLO · Entity 5243 | SaleCommon Stock | 5,000 | $21.00 | $104,994.00 |
DisclosureSEC source: 0001214659-21-008761 · marketforms-53604.xml · nonDerivative · entry 2 Bhavnagri Veer · CIK 0001808980 · General Counsel 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 421,353 F1 · kind: The sale reported in this Form 4 was effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person in December 2020. F2 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $20.82 to $21.34, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth above. Read SEC document |
| August 16, 2021 Filed Aug 17, 2021 16:05 UTC | Allogene Therapeutics, Inc. ALLO · Entity 5243 | Exercise / conversionCommon Stock | 5,000 | $2.27 | $11,350.00 |
DisclosureSEC source: 0001214659-21-008761 · marketforms-53604.xml · nonDerivative · entry 1 Bhavnagri Veer · CIK 0001808980 · General Counsel 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 426,353 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| July 15, 2021 Filed Jul 16, 2021 16:14 UTC | Allogene Therapeutics, Inc. ALLO · Entity 5243 | Exercise / conversionStock Option (Right to Buy) · Derivative | 5,000 | $0.00 Strike: $2.27 | $0.00 |
DisclosureSEC source: 0001214659-21-007588 · marketforms-53417.xml · derivative · entry 3 Bhavnagri Veer · CIK 0001808980 · General Counsel 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 122,300 Underlying: Common Stock · 5,000 shares Expires 2028-06-25 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F3 · derivative.exercise_date: 25% of the shares subject to the stock option vested on April 6, 2019, and the remaining shares vest in 36 equal monthly installments thereafter. Read SEC document |
| July 15, 2021 Filed Jul 16, 2021 16:14 UTC | Allogene Therapeutics, Inc. ALLO · Entity 5243 | SaleCommon Stock | 5,000 | $21.55 | $107,753.00 |
DisclosureSEC source: 0001214659-21-007588 · marketforms-53417.xml · nonDerivative · entry 2 Bhavnagri Veer · CIK 0001808980 · General Counsel 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 421,353 F1 · kind: The sale reported in this Form 4 was effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person in December 2020. F2 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $21.34 to $21.99, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth above. Read SEC document |
| July 15, 2021 Filed Jul 16, 2021 16:14 UTC | Allogene Therapeutics, Inc. ALLO · Entity 5243 | Exercise / conversionCommon Stock | 5,000 | $2.27 | $11,350.00 |
DisclosureSEC source: 0001214659-21-007588 · marketforms-53417.xml · nonDerivative · entry 1 Bhavnagri Veer · CIK 0001808980 · General Counsel 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 426,353 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| June 15, 2021 Filed Jun 16, 2021 17:00 UTC | Allogene Therapeutics, Inc. ALLO · Entity 5243 | Exercise / conversionStock Option (Right to Buy) · Derivative | 5,000 | $0.00 Strike: $2.27 | $0.00 |
DisclosureSEC source: 0001214659-21-006631 · marketforms-53155.xml · derivative · entry 3 Bhavnagri Veer · CIK 0001808980 · General Counsel 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 127,300 Underlying: Common Stock · 5,000 shares Expires 2028-06-25 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F2 · derivative.exercise_date: 25% of the shares subject to the stock option vested on April 6, 2019, and the remaining shares vest in 36 equal monthly installments thereafter. Read SEC document |
| June 15, 2021 Filed Jun 16, 2021 17:00 UTC | Allogene Therapeutics, Inc. ALLO · Entity 5243 | SaleCommon Stock | 5,000 | $25.32 | $126,600.00 |
DisclosureSEC source: 0001214659-21-006631 · marketforms-53155.xml · nonDerivative · entry 2 Bhavnagri Veer · CIK 0001808980 · General Counsel 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 421,353 F1 · kind: The sale reported in this Form 4 was effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person in December 2020. Read SEC document |
| June 15, 2021 Filed Jun 16, 2021 17:00 UTC | Allogene Therapeutics, Inc. ALLO · Entity 5243 | Exercise / conversionCommon Stock | 5,000 | $2.27 | $11,350.00 |
DisclosureSEC source: 0001214659-21-006631 · marketforms-53155.xml · nonDerivative · entry 1 Bhavnagri Veer · CIK 0001808980 · General Counsel 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 426,353 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| May 18, 2021 Filed May 20, 2021 17:19 UTC | Allogene Therapeutics, Inc. ALLO · Entity 5243 | Exercise / conversionStock Option (Right to Buy) · Derivative | 5,000 | $0.00 Strike: $2.27 | $0.00 |
DisclosureSEC source: 0001214659-21-005767 · marketforms-52848.xml · derivative · entry 3 Bhavnagri Veer · CIK 0001808980 · General Counsel 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 132,300 Underlying: Common Stock · 5,000 shares Expires 2028-06-25 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F2 · derivative.exercise_date: 25% of the shares subject to the stock option vested on April 6, 2019, and the remaining shares vest in 36 equal monthly installments thereafter. Read SEC document |
| May 18, 2021 Filed May 20, 2021 17:19 UTC | Allogene Therapeutics, Inc. ALLO · Entity 5243 | SaleCommon Stock | 5,000 | $30.00 | $150,000.00 |
DisclosureSEC source: 0001214659-21-005767 · marketforms-52848.xml · nonDerivative · entry 2 Bhavnagri Veer · CIK 0001808980 · General Counsel 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 421,353 F1 · kind: The sale reported in this Form 4 was effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person in December 2020. Read SEC document |
| May 18, 2021 Filed May 20, 2021 17:19 UTC | Allogene Therapeutics, Inc. ALLO · Entity 5243 | Exercise / conversionCommon Stock | 5,000 | $2.27 | $11,350.00 |
DisclosureSEC source: 0001214659-21-005767 · marketforms-52848.xml · nonDerivative · entry 1 Bhavnagri Veer · CIK 0001808980 · General Counsel 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 426,353 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| May 17, 2021 Filed May 17, 2021 17:16 UTC | Allogene Therapeutics, Inc. ALLO · Entity 5243 | Exercise / conversionStock Option (Right to Buy) · Derivative | 5,000 | $0.00 Strike: $2.27 | $0.00 |
DisclosureSEC source: 0001214659-21-005621 · marketforms-52786.xml · derivative · entry 3 Bhavnagri Veer · CIK 0001808980 · General Counsel 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 137,300 Underlying: Common Stock · 5,000 shares Expires 2028-06-25 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F3 · derivative.exercise_date: 25% of the shares subject to the stock option vested on April 6, 2019, and the remaining shares vest in 36 equal monthly installments thereafter. Read SEC document |
| May 17, 2021 Filed May 17, 2021 17:16 UTC | Allogene Therapeutics, Inc. ALLO · Entity 5243 | SaleCommon Stock | 5,000 | $28.30 | $141,475.50 |
DisclosureSEC source: 0001214659-21-005621 · marketforms-52786.xml · nonDerivative · entry 2 Bhavnagri Veer · CIK 0001808980 · General Counsel 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 421,353 F1 · kind: The sale reported in this Form 4 was effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person in December 2020. F2 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $28.10 to $28.39, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth above. Read SEC document |
| May 17, 2021 Filed May 17, 2021 17:16 UTC | Allogene Therapeutics, Inc. ALLO · Entity 5243 | Exercise / conversionCommon Stock | 5,000 | $2.27 | $11,350.00 |
DisclosureSEC source: 0001214659-21-005621 · marketforms-52786.xml · nonDerivative · entry 1 Bhavnagri Veer · CIK 0001808980 · General Counsel 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 426,353 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| April 15, 2021 Filed Apr 16, 2021 16:07 UTC | Allogene Therapeutics, Inc. ALLO · Entity 5243 | Exercise / conversionStock Option (Right to Buy) · Derivative | 10,000 | $0.00 Strike: $2.27 | $0.00 |
DisclosureSEC source: 0001214659-21-004267 · marketforms-52267.xml · derivative · entry 4 Bhavnagri Veer · CIK 0001808980 · General Counsel 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 142,300 Underlying: Common Stock · 10,000 shares Expires 2028-06-25 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F4 · derivative.exercise_date: 25% of the shares subject to the stock option vested on April 6, 2019, and the remaining shares vest in 36 equal monthly installments thereafter. Read SEC document |
| April 15, 2021 Filed Apr 16, 2021 16:07 UTC | Allogene Therapeutics, Inc. ALLO · Entity 5243 | SaleCommon Stock | 606 | $32.64 | $19,779.72 |
DisclosureSEC source: 0001214659-21-004267 · marketforms-52267.xml · nonDerivative · entry 3 Bhavnagri Veer · CIK 0001808980 · General Counsel 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 421,353 F1 · kind: The sale reported in this Form 4 was effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person in December 2020. F3 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $32.57 to $32.69, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth above. Read SEC document |
| April 15, 2021 Filed Apr 16, 2021 16:07 UTC | Allogene Therapeutics, Inc. ALLO · Entity 5243 | SaleCommon Stock | 9,394 | $32.01 | $300,737.64 |
DisclosureSEC source: 0001214659-21-004267 · marketforms-52267.xml · nonDerivative · entry 2 Bhavnagri Veer · CIK 0001808980 · General Counsel 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 421,959 F1 · kind: The sale reported in this Form 4 was effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person in December 2020. F2 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $31.56 to $32.54, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth above. Read SEC document |
| April 15, 2021 Filed Apr 16, 2021 16:07 UTC | Allogene Therapeutics, Inc. ALLO · Entity 5243 | Exercise / conversionCommon Stock | 10,000 | $2.27 | $22,700.00 |
DisclosureSEC source: 0001214659-21-004267 · marketforms-52267.xml · nonDerivative · entry 1 Bhavnagri Veer · CIK 0001808980 · General Counsel 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 431,353 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| March 26, 2021 Filed Mar 30, 2021 16:55 UTC | Allogene Therapeutics, Inc. ALLO · Entity 5243 | GrantStock Option (Right to Buy) · Derivative | 82,469 | $0.00 Strike: $33.78 | $0.00 |
DisclosureSEC source: 0001214659-21-003607 · marketforms-52126.xml · derivative · entry 2 Bhavnagri Veer · CIK 0001808980 · General Counsel 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 82,469 Underlying: Common Stock · 82,469 shares Expires 2031-03-26 F1 · derivative.exercise_date: 25% of the shares subject to the stock option shall vest on March 13, 2022, and the remaining shares shall vest in 36 equal monthly installments thereafter. Read SEC document |
| March 26, 2021 Filed Mar 30, 2021 16:55 UTC | Allogene Therapeutics, Inc. ALLO · Entity 5243 | GrantCommon Stock | 22,202 | $0.00 | $0.00 |
DisclosureSEC source: 0001214659-21-003607 · marketforms-52126.xml · nonDerivative · entry 1 Bhavnagri Veer · CIK 0001808980 · General Counsel 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 421,353 Read SEC document |
| March 15, 2021 Filed Mar 17, 2021 17:00 UTC | Allogene Therapeutics, Inc. ALLO · Entity 5243 | Exercise / conversionStock Option (Right to Buy) · Derivative | 10,000 | $0.00 Strike: $2.27 | $0.00 |
DisclosureSEC source: 0001214659-21-003242 · marketforms-51923.xml · derivative · entry 5 Bhavnagri Veer · CIK 0001808980 · General Counsel 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 152,300 Underlying: Common Stock · 10,000 shares Expires 2028-06-25 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F6 · derivative.exercise_date: 25% of the shares subject to the stock option vested on April 6, 2019, and the remaining shares vest in 36 equal monthly installments thereafter. Read SEC document |
| March 15, 2021 Filed Mar 17, 2021 17:00 UTC | Allogene Therapeutics, Inc. ALLO · Entity 5243 | SaleCommon Stock | 400 | $38.15 | $15,260.00 |
DisclosureSEC source: 0001214659-21-003242 · marketforms-51923.xml · nonDerivative · entry 4 Bhavnagri Veer · CIK 0001808980 · General Counsel 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 399,151 F4 · kind: The sale reported in this Form 4 was effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person in December 2020. Read SEC document |
| March 15, 2021 Filed Mar 17, 2021 17:00 UTC | Allogene Therapeutics, Inc. ALLO · Entity 5243 | SaleCommon Stock | 9,600 | $37.79 | $362,808.00 |
DisclosureSEC source: 0001214659-21-003242 · marketforms-51923.xml · nonDerivative · entry 3 Bhavnagri Veer · CIK 0001808980 · General Counsel 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 399,551 F4 · kind: The sale reported in this Form 4 was effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person in December 2020. F5 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $37.15 to $38.14, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth above. Read SEC document |
| March 15, 2021 Filed Mar 17, 2021 17:00 UTC | Allogene Therapeutics, Inc. ALLO · Entity 5243 | SaleCommon Stock | 6,623 | $38.16 | $252,730.37 |
DisclosureSEC source: 0001214659-21-003242 · marketforms-51923.xml · nonDerivative · entry 2 Bhavnagri Veer · CIK 0001808980 · General Counsel 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 409,151 F2 · kind: Represents the number of shares sold by the reporting person to cover tax withholding obligations in connection with the vesting of restricted stock units. This sale is mandated by the Issuer's election under its equity incentive plan to require the satisfaction of tax withholding obligations to be funded by a "sell to cover" transaction and does not represent a discretionary trade by the reporting person. F3 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $37.97 to $38.55, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth above. Read SEC document |
| March 15, 2021 Filed Mar 17, 2021 17:00 UTC | Allogene Therapeutics, Inc. ALLO · Entity 5243 | Exercise / conversionCommon Stock | 10,000 | $2.27 | $22,700.00 |
DisclosureSEC source: 0001214659-21-003242 · marketforms-51923.xml · nonDerivative · entry 1 Bhavnagri Veer · CIK 0001808980 · General Counsel 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 415,774 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · balance_after: Includes 372 shares of the Issuer's common stock acquired by the reporting person on March 15, 2021 pursuant to an employee stock purchase program. Read SEC document |
| December 17, 2020 Filed Dec 18, 2020 16:34 UTC | Allogene Therapeutics, Inc. ALLO · Entity 5243 | Exercise / conversionStock Option (Right to Buy) · Derivative | 51,500 | $0.00 Strike: $2.27 | $0.00 |
DisclosureSEC source: 0001214659-20-010544 · marketforms-50661.xml · derivative · entry 2 Bhavnagri Veer · CIK 0001808980 · General Counsel 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 162,300 Underlying: Common Stock · 51,500 shares Expires 2028-06-25 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_date: 25% of the shares subject to the stock option vested on April 6, 2019, and the remaining shares vest in 36 equal monthly installments thereafter. Read SEC document |
| December 17, 2020 Filed Dec 18, 2020 16:34 UTC | Allogene Therapeutics, Inc. ALLO · Entity 5243 | Exercise / conversionCommon Stock | 51,500 | $2.27 | $116,905.00 |
DisclosureSEC source: 0001214659-20-010544 · marketforms-50661.xml · nonDerivative · entry 1 Bhavnagri Veer · CIK 0001808980 · General Counsel 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 405,402 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| October 06, 2020 Filed Oct 8, 2020 17:01 UTC | Allogene Therapeutics, Inc. ALLO · Entity 5243 | Exercise / conversionStock Option (Right to Buy) · Derivative | 10,000 | $0.00 Strike: $2.27 | $0.00 |
DisclosureSEC source: 0001214659-20-008504 · marketforms-49844.xml · derivative · entry 3 Bhavnagri Veer · CIK 0001808980 · General Counsel 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 213,800 Underlying: Common Stock · 10,000 shares Expires 2028-06-25 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F2 · derivative.exercise_date: 25% of the shares subject to the stock option vested on April 6, 2019, and the remaining shares vest in 36 equal monthly installments thereafter. Read SEC document |
| October 06, 2020 Filed Oct 8, 2020 17:01 UTC | Allogene Therapeutics, Inc. ALLO · Entity 5243 | SaleCommon Stock | 10,000 | $40.00 | $400,000.00 |
DisclosureSEC source: 0001214659-20-008504 · marketforms-49844.xml · nonDerivative · entry 2 Bhavnagri Veer · CIK 0001808980 · General Counsel 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 353,902 F1 · kind: The sale reported in this Form 4 was effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person in June 2020. Read SEC document |
| October 06, 2020 Filed Oct 8, 2020 17:01 UTC | Allogene Therapeutics, Inc. ALLO · Entity 5243 | Exercise / conversionCommon Stock | 10,000 | $2.27 | $22,700.00 |
DisclosureSEC source: 0001214659-20-008504 · marketforms-49844.xml · nonDerivative · entry 1 Bhavnagri Veer · CIK 0001808980 · General Counsel 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 363,902 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| October 01, 2020 Filed Oct 2, 2020 16:42 UTC | Allogene Therapeutics, Inc. ALLO · Entity 5243 | Exercise / conversionStock Option (Right to Buy) · Derivative | 25,000 | $0.00 Strike: $2.27 | $0.00 |
DisclosureSEC source: 0001214659-20-008378 · marketforms-49819.xml · derivative · entry 5 Bhavnagri Veer · CIK 0001808980 · General Counsel 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 223,800 Underlying: Common Stock · 25,000 shares Expires 2028-06-25 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F5 · derivative.exercise_date: 25% of the shares subject to the stock option vested on April 6, 2019, and the remaining shares vest in 36 equal monthly installments thereafter. Read SEC document |
| October 01, 2020 Filed Oct 2, 2020 16:42 UTC | Allogene Therapeutics, Inc. ALLO · Entity 5243 | SaleCommon Stock | 800 | $37.73 | $30,180.00 |
DisclosureSEC source: 0001214659-20-008378 · marketforms-49819.xml · nonDerivative · entry 4 Bhavnagri Veer · CIK 0001808980 · General Counsel 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 353,902 F1 · kind: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person in June 2020. F4 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $37.64 to $37.81, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth above. Read SEC document |
| October 01, 2020 Filed Oct 2, 2020 16:42 UTC | Allogene Therapeutics, Inc. ALLO · Entity 5243 | SaleCommon Stock | 7,985 | $37.03 | $295,663.79 |
DisclosureSEC source: 0001214659-20-008378 · marketforms-49819.xml · nonDerivative · entry 3 Bhavnagri Veer · CIK 0001808980 · General Counsel 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 354,702 F1 · kind: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person in June 2020. F3 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $36.62 to $37.49, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth above. Read SEC document |
| October 01, 2020 Filed Oct 2, 2020 16:42 UTC | Allogene Therapeutics, Inc. ALLO · Entity 5243 | SaleCommon Stock | 16,215 | $36.21 | $587,068.94 |
DisclosureSEC source: 0001214659-20-008378 · marketforms-49819.xml · nonDerivative · entry 2 Bhavnagri Veer · CIK 0001808980 · General Counsel 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 362,687 F1 · kind: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person in June 2020. F2 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $35.62 to $36.60, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth above. Read SEC document |
| October 01, 2020 Filed Oct 2, 2020 16:42 UTC | Allogene Therapeutics, Inc. ALLO · Entity 5243 | Exercise / conversionCommon Stock | 25,000 | $2.27 | $56,750.00 |
DisclosureSEC source: 0001214659-20-008378 · marketforms-49819.xml · nonDerivative · entry 1 Bhavnagri Veer · CIK 0001808980 · General Counsel 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 378,902 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| September 01, 2020 Filed Sep 3, 2020 16:12 UTC | Allogene Therapeutics, Inc. ALLO · Entity 5243 | Exercise / conversionStock Option (Right to Buy) · Derivative | 25,000 | $0.00 Strike: $2.27 | $0.00 |
DisclosureSEC source: 0001214659-20-007671 · marketforms-49584.xml · derivative · entry 4 Bhavnagri Veer · CIK 0001808980 · General Counsel 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 248,800 Underlying: Common Stock · 25,000 shares Expires 2028-06-25 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F3 · derivative.exercise_date: 25% of the shares subject to the stock option vested on April 6, 2019, and the remaining shares vest in 36 equal monthly installments thereafter. Read SEC document |
| September 01, 2020 Filed Sep 3, 2020 16:12 UTC | Allogene Therapeutics, Inc. ALLO · Entity 5243 | SaleCommon Stock | 400 | $35.89 | $14,356.00 |
DisclosureSEC source: 0001214659-20-007671 · marketforms-49584.xml · nonDerivative · entry 3 Bhavnagri Veer · CIK 0001808980 · General Counsel 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 353,902 F1 · kind: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on June 11, 2020. Read SEC document |
| September 01, 2020 Filed Sep 3, 2020 16:12 UTC | Allogene Therapeutics, Inc. ALLO · Entity 5243 | SaleCommon Stock | 24,600 | $35.35 | $869,610.00 |
DisclosureSEC source: 0001214659-20-007671 · marketforms-49584.xml · nonDerivative · entry 2 Bhavnagri Veer · CIK 0001808980 · General Counsel 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 354,302 F1 · kind: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on June 11, 2020. F2 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $34.87 to $35.79, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth above. Read SEC document |
| September 01, 2020 Filed Sep 3, 2020 16:12 UTC | Allogene Therapeutics, Inc. ALLO · Entity 5243 | Exercise / conversionCommon Stock | 25,000 | $2.27 | $56,750.00 |
DisclosureSEC source: 0001214659-20-007671 · marketforms-49584.xml · nonDerivative · entry 1 Bhavnagri Veer · CIK 0001808980 · General Counsel 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 378,902 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.